Barclays & Lazard Capital Upgrade Human Genome Sciences (HGSI)
More News related to HGSI
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- After-Hours Movers 11/30: GES, ALTR Higher; NLST, CUTR, LTON, OVTI Lower
- Human Genome Sciences (HGSI) To Offer Up to 12.5M Shares
- Human Genome Sciences Announces Proposed Public Offering of Common Stock
- Citigroup Lifts Price Target on Human Genome Sciences (HGSI) to $38
More News related to Upgrades
- Shares of Brocade (BRCD) Outperforming as Oscar Gruss Upgrades to Buy
- Kinross (KGC) Jumps Higher as Gold Breaks $1,200, JPMorgan Upgrades to Overweight
- Raymond James Upgrades PSS World Medical (PSSI) to Outperform
- Capital One Southcoast Upgrades Penn Virginia (PVA) to Add; Turning Bullish After Data Release
- Raymond James Upgrades CPFL Energia S.A. (CPL) to Outperform
Barclays upgrades Human Genome Sciences (Nasdaq: HGSI) from Equalweight to Overweight
Lazard Capital also upgrades Human Genome Sciences from Hold to Buy.
To see more analyst ratings on HGSI Click Here.
Human Genome Sciences (HGS) is a commercially focused biopharmaceutical company.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
